Synthetic Biology Market (2026 - 2035)

Synthetic Biology Market Research Report: Size, Share, Trend Analysis By Applications (Healthcare, Industrial Biotechnology, Agriculture, Environmental Applications, Food and Nutrition), By Technology (Gene Synthesis, Gene Editing, Synthetic Genomics, Metabolic Engineering, Cloning), By Product Type (Synthetic Genes, Enzymes, Chassis Organisms, Nucleotides, Bioinformatics Tools), By End-use Industry (Pharmaceuticals, Biochemicals, Crop Production, Biofuels, Food and Beverage), and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035
ID: MRFR/HC/9417-HCR
200 Pages
Kinjoll Dey, Snehal Singh
Last Updated: July 12, 2026
Synthetic Biology Market
Market Size
Forecast Period2026-2035
CAGR (2026-2035)17.4%
2025 Market SizeUSD 21.12 Billion
2035 Market SizeUSD 105.04 Billion
Key Players
Thermo Fisher Scientific
Ginkgo Bioworks
Twist Bioscience
Agilent Technologies
Merck KGaA
GenScript Biotech
Trends
  • Declining DNA Synthesis and Sequencing Costs
  • AI-Guided Protein and Pathway Design
  • Government Bio-Economy Funding Mandates
Opportunities
  • Precision Fermentation for Alternative Proteins
  • Biomanufacturing Reshoring and Supply Chain Resilience
  • Emerging-Market Bio-Economy Leapfrogging
Request Free Sample

Synthetic Biology Market Summary

The global Synthetic Biology Market reached USD 21.12 Billion in 2025 and is projected to grow from USD 24.80 Billion in 2026 to USD 105.04 Billion by 2035, registering a CAGR of 17.4% over the forecast period (2026–2035). This trajectory reflects two powerful catalysts: the U.S. Executive Order on Advancing Biotechnology and Biomanufacturing Innovation, which earmarked over USD 2 billion in federal funding for bio-based production capacity [1], and the European Union's updated Horizon Europe work program directing EUR 1.8 billion toward sustainable bio-economy initiatives through 2027 [2]. Taken together, these policy commitments have transformed the Synthetic Biology Market from a research-intensive niche into a scalable industrial platform.

The technology landscape is undergoing a generational shift. Legacy cloning workflows and manual strain-optimization cycles are giving way to AI-guided protein design, automated DNA assembly, and cloud-connected bioreactor networks. Corporate investments in cell-free systems and high-throughput screening have compressed development timelines from years to months. Illumina and partners have driven gene-synthesis costs below USD 0.05 per base pair as of mid-2024, removing a longstanding bottleneck for commercial-scale applications [3]. This cost deflation has opened addressable markets in precision fermentation, bio-based materials, and next-generation therapeutics that were previously uneconomical.

North America commands approximately 46.0% of the Synthetic Biology Market, anchored by a dense cluster of biofoundries and venture-backed startups across Boston, the San Francisco Bay Area, and Research Triangle Park. Asia-Pacific is the fastest-growing region at a projected 19.7% CAGR, driven by aggressive government bio-economy roadmaps in China, India, and South Korea. Europe holds the second-largest share at roughly 24.1%, with strong regulatory frameworks accelerating approval pathways for bio-based chemicals and food ingredients. As public and private capital continue to converge, the Synthetic Biology Market is poised for sustained double-digit expansion through the mid-2030s.

 

Key Report Takeaways

• By Product

  • Core Products held a dominant revenue share of 51.2% in the Synthetic Biology Market in 2025, driven by sustained demand for oligonucleotides, synthetic genes, and chassis organisms across pharmaceutical R&D pipelines.
  • Enabling Products are forecast to expand at an 18.1% CAGR through 2035, as automated DNA assembly platforms and next-generation sequencing kits lower barriers for mid-size biotech firms.

• By Technology

  • Genome Engineering captured 35.4% of market share in 2025, reflecting the widespread commercial deployment of CRISPR-Cas9 and base-editing platforms across therapeutic and agricultural applications.
  • Bioinformatics & CAD Tools are advancing at a 17.8% CAGR, fueled by the integration of machine-learning algorithms into pathway design and strain optimization workflows.

• By Application

  • Healthcare accounted for 57.1% of the Synthetic Biology Market in 2025, with cell and gene therapies, mRNA vaccine platforms, and engineered probiotics as the primary growth vectors.
  • Food & Agriculture is set to rise at a 16.9% CAGR between 2026 and 2035, as precision fermentation and alternative protein platforms gain regulatory clearance in major markets.

• By End User

  • Industrial Biotech Companies commanded a 41.4% share of the Synthetic Biology Market in 2025, reflecting their role as the primary buyers of synthetic DNA, enzymes, and bio-process optimization services.
  • Defense & Government Labs are growing fastest at a 17.5% CAGR, propelled by biosecurity mandates and government-funded biomanufacturing programs.

• By Region

  • North America led with 46.0% market share in 2025, supported by deep venture capital pools and a mature regulatory infrastructure for genetically modified organisms.
  • Asia-Pacific is expanding most rapidly at a 19.7% CAGR, with China's 14th Five-Year Plan for Bio-Economy and India's BioE3 policy initiative serving as primary accelerants.

 

Synthetic Biology Market Size and Forecast (2021–2035)

Market Research Future derives historical estimates from audited financial disclosures of leading synthetic biology companies, patent filings, and government R&D expenditure databases. Forecast projections incorporate bottom-up revenue modeling across product, technology, and application segments, cross-validated against macroeconomic indicators and primary interviews with over 120 industry executives and academic researchers.

Synthetic Biology Market Size and Forecast
Our Impact
Enabled $4.3B Revenue Impact for Fortune 500 and Leading Multinationals
Partnering with 2000+ Global Organizations Each Year
30K+ Citations by Top-Tier Firms in the Industry

Driver Impact Analysis

Driver ~% Impact on CAGR Geographic Relevance Impact Timeline
Declining DNA Synthesis & Sequencing Costs +3.2% Global Short-term (≤2 yr)
AI-Guided Protein & Pathway Design +2.8% North America, Europe Medium-term (2–4 yr)
Government Bio-Economy Funding Mandates +2.5% North America, Asia-Pacific Long-term (≥4 yr)
Corporate Net-Zero & ESG Commitments +2.1% Europe, North America Medium-term (2–4 yr)
Cell & Gene Therapy Pipeline Expansion +1.9% North America, Europe Short-term (≤2 yr)
Precision Fermentation for Alternative Proteins +1.6% Asia-Pacific, North America Medium-term (2–4 yr)
Automated Biofoundry Infrastructure Build-Out +1.4% Global Long-term (≥4 yr)

 

Declining DNA Synthesis and Sequencing Costs

The cost of synthesizing a single base pair of DNA has fallen from approximately USD 0.30 in 2010 to below USD 0.05 in 2024, a trajectory that rivals the semiconductor industry's Moore's Law dynamic [3]. This price deflation directly expands the addressable Synthetic Biology Market by making high-throughput combinatorial library construction economically viable for startups and academic labs alike. Twist Bioscience reported a 18-20% year-over-year increase in orders for synthetic genes in its FY2024 earnings, a demand signal that underscores how cost accessibility translates into revenue acceleration across the value chain [12].

AI-Guided Protein and Pathway Design

Machine-learning models trained on protein structure databases, particularly those based on AlphaFold-like architectures, have decreased the typical protein engineering cycle from 18 months to <4 months [8]. Google DeepMind’s mid-2024 open-source release of AlphaFold 3 sparked a commercial wave, from enzyme optimization in industrial catalysis to innovative antibody design for oncology therapies. The Synthetic Biology Market also directly benefits since AI-designed proteins require synthetic DNA inputs for experimental validation, resulting in a positive feedback loop between computational biology investment and biological parts consumption [13].

 

Government Bio-Economy Funding Mandates

The U.S. Biotechnology and Biomanufacturing Initiative, signed in September 2022, provides over USD 2 billion to government agencies for the expansion of domestic biomanufacturing capacity and workforce training [1]. Likewise, China’s 14th Five-Year Plan for the Bio-Economy allocates CNY 150 Billion (approx. USD 21 Billion) for synthetic biology and biomanufacturing infrastructure up to 2025, with extensions projected in the 15th Plan [14]. These sovereign-sized investments provide multi-year procurement pipelines for DNA synthesis, bioprocess equipment, and analytical software, driving durable demand for the Synthetic Biology Market.

 

Corporate Net-Zero and ESG Commitments

Over 4,500 companies globally have committed to Science Based Targets as of early 2025, creating structural demand for bio-based replacements to petrochemical feedstocks [9]. The Synthetic Biology Market captures this demand through engineered microorganisms that produce sustainable alternatives — from bio-nylon and bio-surfactants to fermentation-derived fragrances.

 

Restraints Impact Analysis

Restraint ~% Impact on CAGR Geographic Relevance Impact Timeline
Dual-Use Biosecurity Regulations −1.8% Global Long-term (≥4 yr)
Skilled Workforce Shortage −1.5% North America, Europe Medium-term (2–4 yr)
Public Perception & GMO Labeling Barriers −1.2% Europe, South America Long-term (≥4 yr)
IP Fragmentation & Patent Thickets −0.9% North America, Asia-Pacific Medium-term (2–4 yr)
Scale-Up Manufacturing Bottlenecks −0.8% Global Short-term (≤2 yr)

 

Dual-Use Biosecurity Regulations

Governments worldwide are tightening oversight of dual-use biological research, creating compliance costs that disproportionately affect smaller players in the Synthetic Biology Market. The U.S. Department of Health and Human Services updated its Screening Framework Guidance for Providers and Users of Synthetic Nucleic Acids in 2023, requiring all synthesis providers to screen orders against expanded select-agent databases [16]. While these measures are essential for public safety, they add 15–20% to order fulfillment timelines for custom gene synthesis, and compliance infrastructure can cost emerging companies USD 2–5 million annually.

Skilled Workforce Shortage

A 2024 survey by the Engineering Biology Research Consortium found that synthetic biology companies in North America and Europe reported difficulty filling mid-career positions in bioprocess engineering and computational biology [17]. The talent gap constrains the Synthetic Biology Market's ability to translate R&D breakthroughs into commercial-scale production. University programs are expanding, but the 4–6 year training pipeline means workforce supply will lag demand through at least 2029, particularly in bioinformatics and fermentation science.

Public Perception and GMO Labeling Barriers

Consumer mistrust over genetically engineered organisms remains a major hurdle for the Synthetic Biology Market, especially in Europe and portions of South America. Even with the European Commission’s proposal for a new regulatory framework for novel genomic techniques in 2023 [18], policy is still being shaped by the 2018 verdict by the European Court of Justice that gene-edited organisms fall under GMO laws. For companies entering the food and agriculture verticals, planning for multi-year regulatory approval processes and consumer education campaigns, which can take up 10–15% of overall product launch expenditures, is also recommended.

 

 

Synthetic Biology Market Opportunities

Precision Fermentation for Alternative Proteins

The worldwide alternative protein industry is predicted to surpass USD 30 billion by 2030. Precision fermentation uses altered yeast or bacteria to create animal-identical proteins and is the Synthetic Biology industry’s most direct avenue into consumer food chains [10]. Companies such as Perfect Day and Remilk have set regulatory precedent for fermentation-derived dairy proteins with their FDA GRAS approvals, reducing the risk for other companies entering the market.

 

Biomanufacturing Reshoring and Supply Chain Resilience

In the wake of pandemic-induced supply chain disruptions, governments in the U.S., EU and Japan are investing in domestic biomanufacturing infrastructure. The U.S. CHIPS and Science Act includes provisions for bio-based manufacturing pilot facilities, while Japan’s Green Transformation (GX) initiative is investing JPY 20 trillion in decarbonization technologies, including industrial biotechnology [21]. This reshoring trend is driving a multi-year demand increase for the Synthetic Biology Market as governments seek to build sovereign capacity in biological production.

 

Emerging-Market Bio-Economy Leapfrogging

Countries such as India, Brazil, and Kenya are bypassing legacy chemical manufacturing by investing directly in bio-based production platforms. India's BioE3 (Bio-Economy, Bio-Energy, Bio-Manufacturing) policy, launched in 2024, represents a greenfield opportunity for the Synthetic Biology Market [22]. Africa's nascent but growing biotech ecosystem — anchored by hubs in Nairobi, Lagos, and Cape Town — offers first-mover advantages for platform companies willing to localize.

Data Monetization Through Design-Build-Test-Learn Platforms

Cloud-based biofoundry platforms that capture design-build-test-learn data are creating recurring-revenue business models that shift the Synthetic Biology Market from one-time reagent sales toward subscription-based analytics services. Ginkgo Bioworks' Foundry platform, for example, generates licensing revenue from proprietary organism designs, effectively monetizing accumulated strain-engineering data [23]. This platform-economics model mirrors the SaaS transition in enterprise software and represents a structural opportunity for margin expansion.

Engineered Living Materials for Construction and Packaging

Self-healing concrete, bio-grown textiles, and mycelium-based packaging represent frontier applications where the Synthetic Biology Market intersects with the USD 15 Trillion global construction industry and the USD 1 Trillion packaging sector [24]. DARPA's Engineered Living Materials program has funded proof-of-concept demonstrations of self-repairing building materials, and commercial prototypes from companies like Biomason (bio-cement) and Ecovative (mycelium packaging) are approaching pilot-scale production.

 

Synthetic Biology Market Future Outlook

AI-Native Biology and Autonomous Labs

The convergence of large language models, protein structure prediction, and robotic laboratory automation will redefine the Synthetic Biology Market over the coming decade. Self-driving labs — where AI algorithms design experiments, robotic platforms execute them, and machine-learning models analyze results in closed loops — are already operational at companies like Recursion Pharmaceuticals and Emerald Cloud Lab [8] [13]. By 2030, Market Research Future expects autonomous design-build-test-learn cycles to compress strain optimization timelines by an additional 60–70%, enabling rapid prototyping of bio-based products at a fraction of current costs.

Platform Economics and Biofoundry-as-a-Service

The Synthetic Biology Market is shifting toward platform-based business models where biofoundries offer design, build, and test services on a subscription or per-project basis. Ginkgo Bioworks processes over 100,000 engineered organisms annually through its Foundry platform, and emerging competitors like Arzeda and Culture Biosciences are building cloud-connected bioreactor networks that democratize access to industrial-scale fermentation [23]. This platformization trend mirrors the cloud computing revolution and is expected to reduce capital intensity for downstream customers by 40–50% over the decade.

Bio-Based Materials and the Circular Economy

Industrial decarbonization mandates — the EU's Carbon Border Adjustment Mechanism, the U.S. Inflation Reduction Act's production tax credits, and China's carbon trading scheme — are creating price signals that favor bio-based over petrochemical production routes [9]. The Synthetic Biology Market stands to capture a growing share of the USD 5 trillion global chemicals market as engineered organisms produce drop-in replacements for nylon, polyester, and surfactants at competitive costs. By 2032, Market Research Future projects that bio-based chemicals will account for approximately 8–10% of total chemical production in OECD countries.

Regulatory Convergence and Biosecurity Governance

International regulatory harmonization will be a defining theme for the Synthetic Biology Market through 2035. The OECD's ongoing work to develop common biosafety assessment frameworks, combined with the Cartagena Protocol's evolving stance on synthetic organisms, will shape market access across geographies [16]. Companies that invest early in compliance infrastructure — including automated sequence-screening systems and transparent reporting mechanisms — will hold a competitive advantage as regulatory barriers rise for underprepared entrants.

 

Synthetic Biology Market Segmentation

By Product

Segment Key Metric Primary Demand Driver
Core Products 51.2% market share (2025) Therapeutic synthetic gene demand, oligonucleotide therapies
Enabling Products 18.1% CAGR (2026–2035) Automated DNA assembly, next-gen sequencing kits
Enabled Products USD 4.56 Billion (2025) Precision fermentation outputs, bio-based chemicals

 

Core Products — encompassing synthetic genes, oligonucleotides, synthetic cells, and chassis organisms — dominate the Synthetic Biology Market because they represent the foundational biological components upon which all downstream applications are built. Demand from pharmaceutical companies for synthetic DNA in mRNA vaccine production and gene therapy manufacturing has been the primary growth engine since 2021 [7]. Enabling Products, which include DNA synthesis platforms, genome-editing kits, and bioinformatics software, represent the fastest-growing product category as automation reduces the marginal cost of experimental iterations. Enabled Products capture the commercial output of synthetic biology — bio-based fuels, cultured ingredients, and engineered enzymes — and are expected to accelerate as precision fermentation plants reach commercial scale in North America and Europe by 2028.

By Technology

Segment Key Metric Primary Demand Driver
Genome Engineering 35.4% market share (2025) CRISPR-Cas9 therapeutic approvals, agricultural gene editing
Bioinformatics & CAD Tools 17.8% CAGR (2026–2035) AI-driven pathway design, cloud lab integration
DNA Synthesis & Assembly USD 3.78 Billion (2025) Gene-synthesis cost deflation, high-throughput screening
Cloning & Sequencing 14.2% CAGR (2026–2035) Long-read sequencing adoption, library construction

 

Genome Engineering is the largest technology segment in the Synthetic Biology Market, reflecting the commercial success of CRISPR-based platforms in both therapeutic and agricultural contexts. The FDA's approval of the first CRISPR-based gene therapy for sickle cell disease in late 2023 marked a watershed moment that validated genome engineering as a mainstream therapeutic modality [7]. Bioinformatics & CAD Tools represent the fastest-growing technology segment as machine-learning models increasingly guide the design of biological circuits, metabolic pathways, and protein structures before physical experimentation begins.

By Application

Segment Key Metric Primary Demand Driver
Healthcare 57.1% market share (2025) Cell/gene therapies, mRNA platforms, engineered diagnostics
Chemicals (Including Biofuels) USD 3.91 Billion (2025) Bio-based intermediates, sustainable aviation fuel
Food & Agriculture 16.9% CAGR (2026–2035) Precision fermentation, gene-edited crops
Other Applications (Biosecurity, Energy, Environment) 15.8% CAGR (2026–2035) Biosurveillance, bioremediation, CO₂ capture

 

Healthcare is the single largest application vertical in the Synthetic Biology Market, driven by a robust clinical pipeline that includes over 300 cell and gene therapy candidates in Phase II/III trials as of 2025 [7]. The chemicals vertical, including biofuels, is expanding as corporate sustainability mandates push demand for bio-based nylon, surfactants, and sustainable aviation fuel. Food & Agriculture is the fastest-growing application, propelled by regulatory approvals for precision fermentation-derived dairy proteins and gene-edited commodity crops in the U.S. and Brazil [10].

By End User

Segment Key Metric Primary Demand Driver
Industrial Biotech Companies 41.4% market share (2025) Bio-based chemical production, enzyme manufacturing
Pharmaceutical & Biotechnology Companies USD 5.72 Billion (2025) Drug discovery, therapeutic development
Academic & Research Institutes 13.9% CAGR (2026–2035) Government grant funding, basic research
Defense & Government Labs 17.5% CAGR (2026–2035) Biosecurity, biomanufacturing resilience

 

Industrial Biotech Companies represent the largest end-user segment in the Synthetic Biology Market, purchasing synthetic DNA, engineered enzymes, and bio-process optimization services at scale for commercial production of bio-based chemicals and materials. Pharmaceutical and biotechnology firms constitute the second-largest buyer group, with spending concentrated on gene synthesis for therapeutic development and clinical manufacturing. Defense & Government Labs are the fastest-growing end-user category, reflecting heightened biosecurity spending and government programs aimed at building sovereign biomanufacturing capacity [1].

 

Regional Market Share Analysis

Region Key Metric Primary Investment Themes
North America 46.0% market share (2025) Venture-backed biofoundries, federal biomanufacturing mandates
Europe 24.1% market share (2025) Green Deal bio-economy, regulatory harmonization for new genomic techniques
Asia-Pacific 19.7% CAGR (2026–2035) Government bio-economy roadmaps, gene-therapy manufacturing
South America USD 1.48 Billion (2025) Agricultural biotech, bio-based fuels
Middle East & Africa 17.8% CAGR (2026–2035) Food security programs, emerging biotech hubs
Total USD 21.12 Billion (2025) —

The Synthetic Biology Market exhibits pronounced geographic concentration, with North America and Europe collectively accounting for over 70% of global revenue in 2025. Regional dynamics are shaped by a combination of regulatory maturity, venture capital availability, and government bio-economy policy frameworks.

 

North America

Country Key Metric Key Driver
US 78.3% of regional share Federal biomanufacturing initiative, deep VC ecosystem
Canada 12.6% of regional share National Biotech Strategy, precision agriculture R&D
Mexico 9.1% of regional share Agricultural biotech adoption, nearshoring trends

 

The United States dominates the North American Synthetic Biology Market, accounting for over three-quarters of regional revenue through a combination of early-mover advantage in CRISPR commercialization, the world's most active biotech venture capital market (USD 15.2 billion deployed into synthetic biology startups in 2023 alone), and favorable FDA regulatory pathways for bio-derived products [1] [6]. Canada's strength centers on agricultural biotechnology and the integration of synthetic biology into its forestry and mining remediation sectors, while Mexico is emerging as a cost-competitive location for contract biomanufacturing.

Europe

Country Key Metric Key Driver
Germany 27.4% of regional share Industrial biotech leadership, Fraunhofer Society R&D
UK 22.8% of regional share SynBioBeta ecosystem, Medicines & Healthcare products Regulatory Agency pathways
France 17.2% of regional share National Bioeconomy Strategy, precision fermentation
Italy 11.5% of regional share Agri-food biotech, bio-based chemicals
Spain 8.3% of regional share Agri-biotech, EU-funded biofoundry projects
Nordic Countries 7.1% of regional share Green transition policies, enzyme engineering
Russia 3.2% of regional share Biofuel mandates, limited VC activity
Rest of Europe 2.5% of regional share Emerging academic programs

 

Europe's Synthetic Biology Market is anchored by Germany and the UK, which together represent half of regional revenue. Germany's industrial biotech ecosystem — led by BASF, Evonik, and the Fraunhofer Society's network of bioprocess research institutes — drives adoption in specialty chemicals and advanced materials [2]. The UK's strength lies in therapeutics, with London and Cambridge serving as global hubs for cell and gene therapy development. The European Commission's proposed regulatory framework for plants produced by new genomic techniques, if enacted, could unlock significant growth in agricultural applications across the continent.

Asia-Pacific

Country Key Metric Key Driver
China 21.3% CAGR 14th Five-Year Bio-Economy Plan, state-backed biofoundries
India 20.8% CAGR BioE3 policy, cost-competitive CRO services
Japan 15.1% CAGR Green Transformation program, enzyme engineering
South Korea 18.6% CAGR K-Bio Strategy, biosimilar manufacturing
ASEAN 16.4% CAGR Agricultural biotech, tropical feedstock optimization
Rest of Asia-Pacific 14.8% CAGR Emerging university research programs

 

Asia-Pacific represents the fastest-growing region in the Synthetic Biology Market, propelled by China's massive state-directed investment in biomanufacturing and India's rapidly expanding contract research ecosystem [14] [22]. China's BGI Group and Genscript Biotech are building vertically integrated platforms that span DNA synthesis, gene editing, and cell therapy manufacturing. Japan's focus on industrial enzyme engineering aligns with its broader Green Transformation strategy, while South Korea's K-Bio initiative targets leadership in biosimilars and advanced biopharmaceuticals. ASEAN nations, particularly Singapore and Thailand, are positioning as regional biomanufacturing hubs with competitive tax incentives and skilled-labor availability.

South America

Country Key Metric Key Driver
Brazil USD 0.89 Billion (2025) Sugarcane-based biorefinery, agricultural GMO adoption
Argentina USD 0.34 Billion (2025) Soy biotech, gene-edited crop approvals
Rest of South America USD 0.25 Billion (2025) Emerging bioeconomy policies

 

Brazil is the dominant force in South America's Synthetic Biology Market, leveraging its established sugarcane ethanol infrastructure and deep agricultural biotechnology expertise. Brazil's National Biosafety Technical Commission (CTNBio) has approved over 100 genetically modified crop events, creating a regulatory environment that is among the most permissive in the developing world [18]. Argentina's early adoption of gene-edited crop regulations positions it as a secondary hub for agricultural synthetic biology applications.

Middle East & Africa

Country Key Metric Key Driver
Saudi Arabia 19.2% CAGR Vision 2030 biotech investment, food security mandates
UAE 18.5% CAGR Dubai BioTech Hub, precision agriculture in arid environments
South Africa 16.3% CAGR Academic research capacity, biofuel development
Egypt 15.7% CAGR Agricultural biotech, Nile Delta food security programs
Rest of MEA 14.9% CAGR Nascent biotech ecosystems

 

The Middle East & Africa region is a nascent but fast-emerging segment of the Synthetic Biology Market, driven primarily by food-security imperatives in water-scarce Gulf states and sub-Saharan Africa. Saudi Arabia's Vision 2030 program includes a dedicated biotech investment vertical targeting precision agriculture and desalination-compatible bio-systems. South Africa anchors the African continent's synthetic biology capacity through its well-established university research infrastructure and growing government interest in bio-based fuels and materials.

 

Synthetic Biology Market By Region, 2025-2035

Competitive Benchmarking

The Synthetic Biology Market exhibits moderate concentration, with the top five players accounting for an estimated 35–40% of global revenue. The Herfindahl-Hirschman Index (HHI) sits in the 800–1,200 range, indicating a moderately fragmented competitive structure where no single company commands dominant pricing power. Competition is intensifying as vertically integrated platform players (Ginkgo Bioworks, Twist Bioscience) challenge incumbent life-science conglomerates (Thermo Fisher, Merck KGaA) across multiple value chain segments.

Company Est. Revenue Share Range Key Offerings for Synthetic Biology Market Strategic Positioning
Thermo Fisher Scientific ~8–11% Synthetic genes, gene-editing reagents, bioprocess instruments Full-stack life sciences supplier with end-to-end workflow coverage
Ginkgo Bioworks ~6–9% Cell programming platform, biofoundry services, licensing Platform-first model monetizing organism design and data assets
Twist Bioscience ~5–8% Synthetic DNA, NGS target enrichment, antibody libraries Silicon-based DNA synthesis technology leader
Agilent Technologies ~4–7% Genomics instruments, SureSelect target enrichment, CRISPR tools Precision measurement and genomics workflow integration
Merck KGaA ~4–6% Gene-editing kits, bioprocess media, synthetic biology reagents Life science division serving pharma and academic R&D
GenScript Biotech ~3–6% Gene synthesis, peptide services, antibody engineering Asia-Pacific cost leader with global delivery infrastructure
Codexis ~2–4% Engineered enzyme platforms, biocatalysis services Proprietary CodeEvolver enzyme engineering platform
Novonesis (formerly Novozymes) ~3–5% Industrial enzymes, microbial solutions, biosolutions Global enzyme manufacturing leader with deep fermentation expertise
Synthego ~2–4% CRISPR kits, synthetic guide RNAs, cell engineering services Automated CRISPR reagent manufacturing and delivery
Integrated DNA Technologies (Danaher) ~3–5% Custom oligonucleotides, gene fragments, CRISPR reagents High-volume nucleic acid synthesis with rapid turnaround

 

 

Recent News & Developments

  • Ginkgo Bioworks (September 2024): Launched its first foundational biological model API to expand public machine-learning access. Simultaneously, the company streamlined operations by divesting its French adaptive evolution subsidiary, Altar, transferring the unit's specialized continuous-cultivation bioreactor technology and teams to fermentation leader Lesaffre.
  • Twist Bioscience (July 2024): Expanded its high-throughput biotherapeutic discovery portfolio by launching a Chinese Hamster Ovary cell line option for Twist Express Antibodies, enabling drug developers to synthesize, clone, and screen sequence-verified candidates within 13 business days.

 

 

  • GenScript Biotech (May 2023): Expanded its core synthesis infrastructure by commissioning a newly automated, 91,310-square-foot oligonucleotide and peptide production facility in Zhenjiang, China, providing high-purity molecular diagnostic reagents, CRISPR gRNAs, and custom peptide libraries at scale.
  • European Commission (July 2023): Table a formal regulatory proposal for plants derived from New Genomic Techniques, establishing a dual-category system that exempts conventional-like NGT-1 crops from rigid, legacy GMO frameworks to accelerate climate-resilient agricultural biotech pipelines across Europe.

 

 

Synthetic Biology Market Report Scope

Parameter Detail
Market Scope Global Synthetic Biology Market covering product, technology, application, end-user, and region
Study Period 2021–2035
CAGR (Forecast Window) 17.4% (2026–2035)
Market Size — Base Year (2025) USD 21.12 Billion
Market Size — Forecast End (2035) USD 105.04 Billion
Fastest Growing Segment (Product) Enabling Products (18.1% CAGR)
Fastest Growing Region Asia-Pacific (19.7% CAGR)
Companies Profiled 10 (Thermo Fisher, Ginkgo Bioworks, Twist Bioscience, Agilent, Merck KGaA, GenScript, Codexis, Novonesis, Synthego, IDT/Danaher)
Valuation Currency USD Billion

 

 

FAQs

How do biofoundry-as-a-service models affect capital requirements for entering the Synthetic Biology Market?
They reduce upfront capital by 40–50% because companies rent automated strain-engineering capacity rather than building proprietary labs. This democratizes access for startups and mid-size firms [23].
What distinguishes CRISPR-based genome editing from older recombinant DNA approaches in commercial synthetic biology applications?
CRISPR offers faster turnaround, multiplexed editing capability, and roughly 70% lower per-edit costs compared to zinc-finger nucleases or TALENs [7]. Commercial adoption has accelerated since the first therapeutic approvals in 2023.
How are insurance and liability frameworks evolving for products derived from the Synthetic Biology Market?
Specialty insurers are developing dedicated bio-product liability policies covering environmental release and allergenicity risks.
What role does cell-free protein synthesis play relative to living-cell-based production in the Synthetic Biology Market?
Cell-free systems excel in rapid prototyping and toxic-protein production, offering 10x faster iteration cycles. Living-cell systems retain advantages for high-volume, low-cost commodity production at industrial scale [11].
How do export control regimes on synthetic nucleic acids impact cross-border trade in the Synthetic Biology Market?
Updated U.S. and EU screening mandates add 15–20% to fulfillment timelines for international gene-synthesis orders. Companies with multi-country manufacturing footprints can partially offset these delays [16].
What procurement criteria should industrial buyers prioritize when selecting a synthetic DNA supplier?
Buyers should evaluate sequence accuracy rates, turnaround time, biosecurity screening compliance, and long-fragment assembly capability. Volume pricing tiers and geographic fulfillment coverage are secondary but material considerations [12].
How does the Synthetic Biology Market intersect with carbon credit and voluntary carbon offset mechanisms?
Bio-based production processes generating verified emissions reductions can qualify for voluntary carbon credits under standards like Verra and Gold Standard [9]. This creates an ancillary revenue stream.    
Author
Author
Author Profile
Kinjoll Dey LinkedIn
Senior Research Analyst
He is an extremely curious individual currently working in Healthcare and Medical Devices Domain. Kinjoll is comfortably versed in data centric research backed by healthcare educational background. He leverages extensive data mining and analytics tools such as Primary and Secondary Research, Statistical Analysis, Machine Learning, Data Modelling. His key role also involves Technical Sales Support, Client Interaction and Project management within the Healthcare team. Lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Co-Author
Co-Author Profile
Snehal Singh LinkedIn
Manager - Research
High acumen in analyzing complex macro & micro markets with more than 6 years of work experience in the field of market research. By implementing her analytical skills in forecasting and estimation into market research reports, she has expertise in Packaging, Construction, and Equipment domains. She handles a team size of 20-25 resources and ensures smooth running of the projects, associated marketing activities, and client servicing.
Get In Touch
Download Free Sample

Kindly complete the form below to receive a free sample of this Report

No regional reports available for this market.

Customer Stories

Case Study Cover Image
Case Study
Aerospace & Defense
Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035
Download PDF ×

We do not share your information with anyone. However, we may send you emails based on your report interest from time to time. You may contact us at any time to opt-out.